Roivant Sciences (ROIV) concentration risks

The company's concentration profile is defined by two high-share exposures that are pre-commercial in nature: a pipeline dependency and a licensing counterparty dependency, both of which carry meaningful binary event risk. On the pipeline side, the company's near-term value inflection is centered on brepocitinib, a candidate for which the FDA has accepted a filing with Priority Review and a PDUFA target action date in the third quarter of calendar year 2026. This is a high-share, mixed-character exposure: the program represents a defined near-term catalyst, but the outcome is binary — approval would be a meaningful value event, while a refusal or complete response letter would remove a significant source of expected near-term value. The concentration is not merely structural but is tied to regulatory timing that is now close. Separately, a high-share dependency exists on HanAll Biopharma Co., Ltd., from whom Immunovant holds intellectual property rights to IMVT-1402 and batoclimab under a license agreement. This is a dependency exposure: the company does not own these rights outright, and the value of the relevant programs is contingent on the license agreement remaining in good standing. Any dispute, termination, or renegotiation of that relationship would directly impair the programs in question. The two exposures — a near-term regulatory event on one asset and a licensing counterparty dependency on others — are distinct in mechanism but both represent idiosyncratic, event-driven risks that are material at the current stage of the business.

For the engine’s reasoning on ROIV’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.